ArticleCryobiology2013
Amphipathic polymer-mediated uptake of trehalose for dimethyl sulfoxide-free human cell cryopreservation.
Article in Cryobiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 35 citations in OpenAlex.
- Trehalose in cryopreservation. Applications, mechanisms and intracellular delivery opportunities.RSC medicinal chemistry · 2024Review
- Advanced cryopreservation engineering strategies: the critical step to utilize stem cell products.Cell regeneration (London, England) · 2023Review
- Review
- Rediscovery of poly(ethylene glycol)s as a cryoprotectant for mesenchymal stem cells.Biomaterials research · 2023Article
- Chemical approaches to cryopreservation.Nature reviews. Chemistry · 2022Review
- Formulation Considerations for Autologous T Cell Drug Products.Pharmaceutics · 2021Review
- Article
- Ice Inhibition for Cryopreservation: Materials, Strategies, and Challenges.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Review
- Post-Thaw Culture and Measurement of Total Cell Recovery Is Crucial in the Evaluation of New Macromolecular Cryoprotectants.Biomacromolecules · 2020Article
- Polyampholytes as Emerging Macromolecular Cryoprotectants.Biomacromolecules · 2020Review
- Intracellular Delivery of Trehalose for Cell Banking.Langmuir : the ACS journal of surfaces and colloids · 2019Review
- Article
- StemCell Keep™ Is Effective for Cryopreservation of Human Embryonic Stem Cells by Vitrification.Cell transplantation · 2017Article
- Cryopreservation of Human Adipose-Derived Stem Cells in Combination with Trehalose and Reversible Electroporation.The Journal of membrane biology · 2017Article
- Engineered Trehalose Permeable to Mammalian Cells.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
For stem cell therapy to become a routine reality, one of the major challenges to overcome is their storage and transportation. Currently this is achieved by cryopreserving cells utilising the cryoprotectant dimethyl sulfoxide (Me2SO). Me2SO is toxic to cells, leads to loss of cell functionality, and can produce severe side effects in patients. Potentially, cells could be frozen using the cryoprotectant trehalose if it could be delivered into the cells at a sufficient concentration. The novel amphipathic membrane permeabilising agent PP-50 has previously been shown to enhance trehalose uptake by erythrocytes, resulting in increased cryosurvival. Here, this work was extended to the nucleated human cell line SAOS-2. Using the optimum PP-50 concentration and media osmolarity, cell viability post-thaw was 60 ± 2%. In addition, the number of metabolically active cells 24h post-thaw, normalised to that before freezing, was found to be between 103 ± 4% and 91 ± 5%. This was found to be comparable to cells frozen using Me2SO. Although reduced (by 22 ± 2%, p=0.09), the doubling time was found not to be statistically different to the non-frozen control. This was in contrast to cells frozen using Me2SO, where the doubling time was significantly reduced (by 41 ± 4%, p=0.004). PP-50 mediated trehalose delivery into cells could represent an alternative cryopreservation protocol, suitable for research and therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.